References
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al.: Cancer statistics, 2008. CA Cancer J Clin 58(2), 71–96, 2008.
- Gerber M: Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br J Nutr 107(Suppl. 2), S228–S239, 2012.
- Park SY, Wilkens LR, Henning SM, Le ML, Gao K, et al.: Circulating fatty acids and prostate cancer risk in a nested case-control study: the Multiethnic Cohort. Cancer Causes Control 20, 211–223, 2009.
- Chavarro JE, Stampfer MJ, Li H, Campos H, Kurth T, et al.: A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16, 1364–1370, 2007.
- Brasky TM, Till C, White E, Neuhouser ML, Song X, et al.: Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 173, 1429–1439, 2011.
- Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, et al.: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 105, 1132–1141, 2013.
- Chua ME, Sio MC, Sorongon MC, and Morales ML, Jr.: The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: A meta-analysis. Can Urol Assoc J 7, E333–E343, 2013.
- Hamazaki K, Higashihara E, Terachi T, Takada H, Matsuda T, et al.: The effect of eicosapentaenoic acid on prostate-specific antigen. In Vivo 20, 397–401, 2006.
- Safarinejad MR, Shafiei N, and Safarinejad S: Effects of EPA, gamma-linolenic acid or coenzyme Q10 on serum prostate-specific antigen levels: a randomised, double-blind trial. Br J Nutr 110, 164–171, 2013.
- Blair SN, Kohl HW, III, Paffenbarger RS, Jr., Clark DG, Cooper KH, et al.: Physical fitness and all-cause mortality: a prospective study of healthy men and women. JAMA 262, 2395–2401, 1989.
- Harris WS, Pottala JV, Vasan RS, Larson MG, and Robins SJ: Changes in erythrocyte membrane trans and marine fatty acids between 1999 and 2006 in older Americans. J Nutr 142, 1297–1303, 2012.
- Harris WS, Pottala JV, Lacey SM, Vasan RS, Larson MG, et al.: Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study. Atherosclerosis 225, 425–431, 2012.
- Harris WS: The omega-3 index: clinical utility for therapeutic intervention. Curr Cardiol Rep 12, 503–508, 2010.
- Harris WS, Pottala JV, Varvel SA, Borowski JJ, Ward JN, et al.: Erythrocyte omega-3 fatty acids increase and linoleic acid decreases with age: observations from 160,000 patients. Prostaglandins Leukot Essent Fatty Acids 88, 257–263, 2013.
- Crowe FL, Appleby PN, Travis RC, Barnett M, Brasky TM, et al. Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. J Natl Cancer Inst 106, 2014.
- Harris WS and Davidson MH: RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 106(4), dju019, 2014.
- EFSA Panel on Dietetic Products NaA: Scientific opinion on the extension of use for DHA and EPA-rich algal oil from Schizochytrium sp. as a novel food ingredient. EFSA Journal 12, 3843–3860, 2014.
- Baylin A, Kim MK, Donovan-Palmer A, Siles X, Dougherty L, et al.: Fasting whole blood as a biomarker of essential fatty acid intake in epidemiologic studies: comparison with adipose tissue and plasma. Am J Epidemiol 162, 373–381, 2005.
- Harris WS and Thomas RM: Biological variability of blood omega-3 biomarkers. Clin Biochem 43, 338–340, 2010.
- Fontes JD, Rahman F, Lacey S, Larson MG, Vasan RS, et al.: Red blood cell fatty acids and biomarkers of inflammation: A cross-sectional study in a community-based cohort. Atherosclerosis 240, 431–436, 2015.